Loading organizations...
§ Venture Capital · Liège, Liege, Belgium
Public information on this organization's operations, services, business model, and market focus is currently unavailable.
Biognosys provides proteomics solutions and contract research services for comprehensive proteome analysis. Its TrueDiscovery platforms and proprietary software deliver insights into protein expression and function. The company assists biomarker discovery and drug target identification, offering precise protein quantification for biopharma research and development.
Oliver Rinner and Roland Bruderer founded Biognosys in 2008, spinning off from Ruedi Aebersold's proteomics lab at ETH Zurich. Their insight recognized demand for robust, high-performance technologies to accurately decode the proteome. This aimed to accelerate biological and clinical research through enhanced protein analysis precision.
Pharmaceutical and biotechnology firms, academics, and clinical researchers leverage Biognosys for drug discovery, preclinical studies, and clinical trials. Its vision is to advance precision medicine, transforming disease diagnosis, treatment, and prevention. It transitions proteomics discoveries from research into impactful clinical realities across diverse therapeutic areas.
Biogenosis has 2 tracked investments across 1 company. The latest tracked deal is $25.8M Series B Extension in Imcyse in February 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 17, 2021 | Imcyse | $25.8M Series B Extension | — | Epimede, KU Leuven, LSP, Noshaq, Pfizer, Sfpi Fpim, Sriw |
| Jun 18, 2019 | Imcyse | $38.8M Debt / Grant / Series B | LSP | Belfius, Dgo6, Marc Moles LE Bailly, Paul VAN DUN, Marc Foidart, Fontaine François, Franssen Christina |